79 / 116
787
Veglio F. Drug effects on aldosterone/plasma renin activity ratio
in primary aldosteronism. Hypertension 2002;40:897-902.
32. Fischer E, Beuschlein F, Bidlingmaier M, Reincke M.
Commentary on the Endocrine Society Practice Guidelines:
Consequences of adjustment of antihypertensive medication in
screening of primary aldosteronism. Rev Endocr Metab Disord.
2011;12(1):43-8.
33. Stowasser M, Gordon RD. Primary aldosteronism. Best Pract
ResClin Endocrinol Metab. 2003;17:591–605.
34. Miller WL, Auchus RJ. The molecular biology, biochemistry, and
physiology of human steroidogenesis and its disorders. Endocr
Rev. 2011;32:81-151
35. Webb EA, Krone N. Current and novel approaches to children
and young people with congenital adrenal hyperplasia and
adrenal insufficiency. Best Pract Res Clin Endocrinol Metab.
2015;29:449-68
36. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J
Med 2003; 349: 776-788.
37. Lenders JW, Pacak K, Walther MM, et al Biochemical diagnosis of
pheochromocytoma: wich test is best? JAMA. 2002; 287:1427-
1434
38. YuR, WeiM. False positive test results for pheochromocytoma from
2000 to 2008.ExpClin Endocrinol Diabetes. 2010;118:577–
585.
39. Lenders JW, Duh QY, Eisenhofer G et al. Pheochromocytoma and
Paraganglioma: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab 2014; 99: 1915-1942.
40. Murray J. Favus and David Goltzman. Regulation of Calcium
and Magnesium. Editado por Clifford J. Rosen. Primer on the
Metabolic Bone Diseases and Disorders of Mineral Metabolism,
8° edición. John Wiley & Sons, Inc 2013 American Society for
Bone and Mineral Research. Págs 173-180.
41. Cavalier E, Delanaye P, Nyssen L et al. Problems with the PTH
assays. Ann Endocrinol (Paris). 2015;76:128-33
42. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-8.
43. Minisola S, Pepe J, Piemonte S et al. The diagnosis and
management of hypercalcaemia. BMJ 2015;351:h3655.
[Laboratorio de hormonas: aspectos prácticos - Dr. René E. Díaz T. y cols.]